IL269133B2 - Eye Drops for Treatment of Sj?gren's Syndrom - Google Patents

Eye Drops for Treatment of Sj?gren's Syndrom

Info

Publication number
IL269133B2
IL269133B2 IL269133A IL26913319A IL269133B2 IL 269133 B2 IL269133 B2 IL 269133B2 IL 269133 A IL269133 A IL 269133A IL 26913319 A IL26913319 A IL 26913319A IL 269133 B2 IL269133 B2 IL 269133B2
Authority
IL
Israel
Prior art keywords
ophthalmic preparation
aqueous solution
glycerol
irritation
treatment
Prior art date
Application number
IL269133A
Other languages
English (en)
Hebrew (he)
Other versions
IL269133B1 (en
IL269133A (en
Inventor
Shabtay Dikstein
Original Assignee
Resdevco Res And Development Co Ltd
Shabtay Dikstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resdevco Res And Development Co Ltd, Shabtay Dikstein filed Critical Resdevco Res And Development Co Ltd
Publication of IL269133A publication Critical patent/IL269133A/en
Publication of IL269133B1 publication Critical patent/IL269133B1/en
Publication of IL269133B2 publication Critical patent/IL269133B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL269133A 2017-03-05 2018-02-19 Eye Drops for Treatment of Sj?gren's Syndrom IL269133B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762467139P 2017-03-05 2017-03-05
PCT/IL2018/050184 WO2018163151A1 (en) 2017-03-05 2018-02-19 Eye drops for treatment of irritation not due to infection

Publications (3)

Publication Number Publication Date
IL269133A IL269133A (en) 2019-11-28
IL269133B1 IL269133B1 (en) 2024-05-01
IL269133B2 true IL269133B2 (en) 2024-09-01

Family

ID=61656085

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269133A IL269133B2 (en) 2017-03-05 2018-02-19 Eye Drops for Treatment of Sj?gren's Syndrom

Country Status (14)

Country Link
US (2) US11033513B2 (enExample)
EP (2) EP4385565A3 (enExample)
JP (1) JP7258778B2 (enExample)
KR (1) KR102652879B1 (enExample)
CN (1) CN110891555B (enExample)
AU (1) AU2018230262B2 (enExample)
BR (1) BR112019018367A2 (enExample)
CA (1) CA3055523C (enExample)
ES (1) ES3036888T3 (enExample)
IL (1) IL269133B2 (enExample)
MX (1) MX388961B (enExample)
PL (1) PL3592339T3 (enExample)
RU (1) RU2019130955A (enExample)
WO (1) WO2018163151A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123324A1 (en) * 2005-05-16 2006-11-23 Resdevco Research And Development Co. Ltd., Topical compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5895645A (en) * 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
AR004214A1 (es) 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
IL212725A (en) * 2011-05-05 2016-06-30 Resdevco Res And Dev Co Glycerol Preparation for Non-surgical Conjunctivochalysis
EP2783689B1 (en) * 2011-11-24 2019-09-25 Toyo Sugar Refining Co., Ltd. Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123324A1 (en) * 2005-05-16 2006-11-23 Resdevco Research And Development Co. Ltd., Topical compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS:, SJGREN’S SYNDROME, 27 February 2017 (2017-02-27) *
GENSHEIMER WILLIAM G., ET AL.:, NOVEL FORMULATION OF GLYCERIN 1% ARTIFICIAL TEARS EXTENDS TEAR FILM BREAK-UP TIME COMPARED WITH SYSTANE LUBRICANT EYE DROPS., 31 December 2012 (2012-12-31) *
KISS HUBA J., AND JANOS NEMETH:, ISOTONIC GLYCEROL AND SODIUM HYALURONATE CONTAINING ARTIFICIAL TEAR DECREASES CONJUNCTIVOCHALASIS AFTER ONE AND THREE MONTHS: A SELF-CONTROLLED, UNMASKED STUDY., 14 July 2015 (2015-07-14) *
SCRIVANTI M ET AL:, DRY EYE SYNDROME: HYALURONIC ACID EYE DROP (LO2A), 31 December 1996 (1996-12-31) *
SOLOMON ABRAHAM, AND SAUL MERIN:, THE EFFECT OF A NEW TEAR SUBSTITUTE CONTAINING GLYCEROL AND HYALURONATE ON KERATOCONJUNCTIVITIS SICCA., 1 December 1998 (1998-12-01) *

Also Published As

Publication number Publication date
WO2018163151A1 (en) 2018-09-13
CA3055523A1 (en) 2018-09-13
US20210186892A1 (en) 2021-06-24
PL3592339T3 (pl) 2025-09-01
IL269133B1 (en) 2024-05-01
CN110891555A (zh) 2020-03-17
US11033513B2 (en) 2021-06-15
CA3055523C (en) 2024-10-01
US11426361B2 (en) 2022-08-30
KR102652879B1 (ko) 2024-03-29
RU2019130955A3 (enExample) 2021-06-24
US20190388361A1 (en) 2019-12-26
JP7258778B2 (ja) 2023-04-17
AU2018230262A1 (en) 2019-09-26
AU2018230262B2 (en) 2024-01-18
EP3592339C0 (en) 2025-04-30
JP2020509092A (ja) 2020-03-26
EP3592339B1 (en) 2025-04-30
KR20190129065A (ko) 2019-11-19
BR112019018367A2 (pt) 2020-04-07
CN110891555B (zh) 2023-12-26
IL269133A (en) 2019-11-28
EP4385565A2 (en) 2024-06-19
EP3592339A1 (en) 2020-01-15
MX2019010471A (es) 2020-02-12
RU2019130955A (ru) 2021-04-07
ES3036888T3 (en) 2025-09-25
EP4385565A3 (en) 2024-08-21
MX388961B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
Cheng et al. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
EP3914244A1 (en) Pharmaceutical composition for the treatment of ocular neovascularisation
JP2005513106A (ja) ヘパリンを保有する眼薬剤
Abbate et al. Preclinical study of a new matrix to help the ocular surface in dry eye disease
IL269133B1 (en) Eye Drops for Treatment of Sj?gren's Syndrom
CN110913867B (zh) 热凝胶化人工泪液
Camillieri et al. Effects of hyaluronan on free-radical formation, corneal endothelium damage, and inflammation parameters after phacoemulsification in rabbits
US20090175972A1 (en) Synergistic herbal ophthalmic formulation for lowering intraocular pressure in case of glaucoma
EP3758688B1 (en) Nk-1 antagonists for use in the treatment of ocular pain
CN118510520A (zh) 用于治疗眼部疾病的霉酚酸和/或倍他米松的药物组合物
EP3150211A1 (en) Therapeutic agent for keratoconjunctive disorder
US20250360185A1 (en) Compositions comprising pedf-derived short peptides for the treatment of dry eye diseases
Chen et al. Exosomal miR-146a derived from human umbilical cord mesenchymal stem cells alleviates inflammation and apoptosis in dry eye disease by targeting SQSTM1
US8912166B2 (en) Eye drops for treatment of conjunctivochalasis
EP4454639A1 (en) Ophthalmic composition comprising carbomer and taurine
US11253565B2 (en) Nanoparticle ophthalmic composition for the treatment of ocular disorders or diseases
US20230134843A1 (en) Treatment of stem cell deficiency
Kudyar et al. Comparison of efficacy of treatment with cyclosporine 0.1% add on therapy with artificial tears (carboxy methyl cellulose 0.5%) & artificial tears alone on dry eye parameters in post cataract surgery patients
Toto et al. Steroid-Nitroxide Hybrid Compound Protects the Retina
CN120661442A (zh) 一种滴眼液的组合物及其制备方法和应用
Kwatra et al. Routes of Ocular Drug Delivery-Conventional vs. Novel Routes